Status:
WITHDRAWN
Treatment of Alcohol-Related Hepatitis With Arginine
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)
Collaborating Sponsors:
Office of Dietary Supplements (ODS)
Conditions:
Alcoholic Hepatitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test the effectiveness of the amino acid arginine in reducing liver injury in individuals with alcohol-related hepatitis.
Detailed Description
Arginine is a naturally occurring amino acid that is also available in pill form. Arginine pills have been shown to aid in liver detoxification and fat breakdown in the liver. Numerous studies have ex...
Eligibility Criteria
Inclusion
- Diagnosis of alcoholic hepatitis
- Maddrey's DF score less than 33
Exclusion
- Hepatitis C or B virus infected
- HIV infected
- History of cancer
- Hepatic encephalopathy (a condition in which liver failure affects the central nervous system)
- Kidney failure
- A Do Not Resuscitate order (a patient-directed order not to resuscitate in the event that resuscitation is necessary to prevent death)
- Maddrey's DF score of 33 or greater after vitamin K administration during the study
- Alcohol withdrawal at study entry
- Active pneumonia at study entry
- Allergy to iodine
- Enrollment in any other clinical trials
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00200746
Start Date
April 1 2006
End Date
July 1 2009
Last Update
March 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harbor - University of California Los Angeles Medical Center
Torrance, California, United States, 90509